CAMBRIDGE, Mass. (Financial Times) -- The chief executive of Moderna has predicted that existing vaccines will be much less effective at tackling omicron than earlier strains of Covid-19 and warned it would take months before pharmaceutical companies can manufacture new variant-specific jabs at scale.
